“FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects”
The study will comprise primarily a single-ascending dose (SAD) escalation component.
Drug - GFB-887
Drug - Placebo
A First-In-Human, Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-887, a TRPC5 Channel Inhibitor, in Healthy Subjects